Cargando…

Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE

OBJECTIVE: Treat-to-target (T2T) strategies are advocated to improve prognosis in childhood-onset SLE (cSLE). Proposed T2T states include SLEDAI score of <4 (SLEDAI-LD), limited corticosteroid use (low-CS), and lupus low disease activity state (LLDAS). We sought to compare T2T states for their as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cody, Ellen M, Wilson, Bridget E, Ogbu, Ekemini A, Huggins, Jennifer L, Chen, Chen, Qiu, Tingting, Ting, Tracy V, Flores, Francisco, Huang, Bin, Brunner, Hermine I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230998/
https://www.ncbi.nlm.nih.gov/pubmed/37253553
http://dx.doi.org/10.1136/lupus-2022-000884
_version_ 1785051658642784256
author Cody, Ellen M
Wilson, Bridget E
Ogbu, Ekemini A
Huggins, Jennifer L
Chen, Chen
Qiu, Tingting
Ting, Tracy V
Flores, Francisco
Huang, Bin
Brunner, Hermine I
author_facet Cody, Ellen M
Wilson, Bridget E
Ogbu, Ekemini A
Huggins, Jennifer L
Chen, Chen
Qiu, Tingting
Ting, Tracy V
Flores, Francisco
Huang, Bin
Brunner, Hermine I
author_sort Cody, Ellen M
collection PubMed
description OBJECTIVE: Treat-to-target (T2T) strategies are advocated to improve prognosis in childhood-onset SLE (cSLE). Proposed T2T states include SLEDAI score of <4 (SLEDAI-LD), limited corticosteroid use (low-CS), and lupus low disease activity state (LLDAS). We sought to compare T2T states for their association with cSLE prognosis under consideration of relevant disease characteristics such as pre-existing damage, race and lupus nephritis (LN). METHODS: Longitudinal data from 165 patients enrolled in the Cincinnati Lupus Registry were included. LN presence was based on renal biopsy, and patients were followed up until 18 years of age. RESULTS: The 165 patients (LN: 45, white: 95) entered the registry within a median of 0 (IQR: 0–1) year post diagnosis and were followed up for a median of 4 (IQR: 2–5) years during which 80%, 92% and 94% achieved LLDAS, low-CS and SLEDAI-LD. Patients with LN were significantly less likely to achieve any T2T state (all p<0.03) and required a significantly longer time to reach them (all p<0.0001). Over the study period, patients maintained low-CS, SLEDAI-LD or LLDAS for a median of 76% (IQR: 48%–100%), 86% (IQR: 55%–100%) or 39% (IQR: 13%–64%) of their follow-up. Significant predictors of failure to maintain LLDAS included LN (p≤0.0062), pre-existing damage (p≤0.0271) and non-white race (p≤0.0013). There were 22%, 20% and 13% of patients who reached SLEDAI-LD, CS-low and LLDAS and nonetheless acquired new damage. Patients with LN had a higher risk of new damage than patients without LN even if achieving low-CS (p=0.009) or LLDAS (p=0.04). CONCLUSIONS: Patients with LN and pre-existing damage are at higher risk of increased future damage acquisition, even if achieving a T2T state such as LLDAS. Among proposed common T2T states, the LLDAS is the hardest to achieve and maintain. The LLDAS may be considered the preferred T2T measure as it conveys the highest protection from acquiring additional disease damage.
format Online
Article
Text
id pubmed-10230998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102309982023-06-01 Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE Cody, Ellen M Wilson, Bridget E Ogbu, Ekemini A Huggins, Jennifer L Chen, Chen Qiu, Tingting Ting, Tracy V Flores, Francisco Huang, Bin Brunner, Hermine I Lupus Sci Med Childhood Lupus OBJECTIVE: Treat-to-target (T2T) strategies are advocated to improve prognosis in childhood-onset SLE (cSLE). Proposed T2T states include SLEDAI score of <4 (SLEDAI-LD), limited corticosteroid use (low-CS), and lupus low disease activity state (LLDAS). We sought to compare T2T states for their association with cSLE prognosis under consideration of relevant disease characteristics such as pre-existing damage, race and lupus nephritis (LN). METHODS: Longitudinal data from 165 patients enrolled in the Cincinnati Lupus Registry were included. LN presence was based on renal biopsy, and patients were followed up until 18 years of age. RESULTS: The 165 patients (LN: 45, white: 95) entered the registry within a median of 0 (IQR: 0–1) year post diagnosis and were followed up for a median of 4 (IQR: 2–5) years during which 80%, 92% and 94% achieved LLDAS, low-CS and SLEDAI-LD. Patients with LN were significantly less likely to achieve any T2T state (all p<0.03) and required a significantly longer time to reach them (all p<0.0001). Over the study period, patients maintained low-CS, SLEDAI-LD or LLDAS for a median of 76% (IQR: 48%–100%), 86% (IQR: 55%–100%) or 39% (IQR: 13%–64%) of their follow-up. Significant predictors of failure to maintain LLDAS included LN (p≤0.0062), pre-existing damage (p≤0.0271) and non-white race (p≤0.0013). There were 22%, 20% and 13% of patients who reached SLEDAI-LD, CS-low and LLDAS and nonetheless acquired new damage. Patients with LN had a higher risk of new damage than patients without LN even if achieving low-CS (p=0.009) or LLDAS (p=0.04). CONCLUSIONS: Patients with LN and pre-existing damage are at higher risk of increased future damage acquisition, even if achieving a T2T state such as LLDAS. Among proposed common T2T states, the LLDAS is the hardest to achieve and maintain. The LLDAS may be considered the preferred T2T measure as it conveys the highest protection from acquiring additional disease damage. BMJ Publishing Group 2023-05-30 /pmc/articles/PMC10230998/ /pubmed/37253553 http://dx.doi.org/10.1136/lupus-2022-000884 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Childhood Lupus
Cody, Ellen M
Wilson, Bridget E
Ogbu, Ekemini A
Huggins, Jennifer L
Chen, Chen
Qiu, Tingting
Ting, Tracy V
Flores, Francisco
Huang, Bin
Brunner, Hermine I
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title_full Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title_fullStr Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title_full_unstemmed Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title_short Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
title_sort usefulness of the lupus low disease activity state as a treatment target in childhood-onset sle
topic Childhood Lupus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230998/
https://www.ncbi.nlm.nih.gov/pubmed/37253553
http://dx.doi.org/10.1136/lupus-2022-000884
work_keys_str_mv AT codyellenm usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT wilsonbridgete usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT ogbuekeminia usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT hugginsjenniferl usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT chenchen usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT qiutingting usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT tingtracyv usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT floresfrancisco usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT huangbin usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle
AT brunnerherminei usefulnessofthelupuslowdiseaseactivitystateasatreatmenttargetinchildhoodonsetsle